Citations

Citations to this article as recorded by  

• Effect of Different Types of Antithrombotic Agents on Clinical Outcomes in Patients With Small Bowel Bleeding Who Underwent Balloon‐Assisted Enteroscopy: A KASID Multicenter Study
  Jihye Park, Jin Su Kim, Joo Hye Song, Kwangwoo Nam, Seong‐Eun Kim, Eui Sun Jeong, Jae Hyun Kim, Seong Ran Jeon
  Journal of Gastroenterology and Hepatology.2025; 40(2): 456.     CrossRef
• Balloon-assisted enteroscopy in the management of adult small-bowel intussusception: a comparative analysis of with and without double-balloon enteroscopy
  Won Shik Kim, Beom Jae Lee, Moon Kyung Joo, Seung Han Kim, Jong-Jae Park
  Surgical Endoscopy.2025; 39(3): 2044.     CrossRef
• From Data to Insights: How Is AI Revolutionizing Small-Bowel Endoscopy?
  Joana Mota, Maria João Almeida, Francisco Mendes, Miguel Martins, Tiago Ribeiro, João Afonso, Pedro Cardoso, Helder Cardoso, Patrícia Andrade, João Ferreira, Miguel Mascarenhas, Guilherme Macedo
  Diagnostics.2024; 14(3): 291.     CrossRef
• Role of Device-Assisted Enteroscopy in Crohn’s Disease
  Giulia Catassi, Clelia Marmo, Antonio Gasbarrini, Maria Elena Riccioni
  Journal of Clinical Medicine.2024; 13(13): 3919.     CrossRef
• Discordance Rate and Risk Factor of Other Diagnostic Modalities for Small Bowel Tumors Detected by Device-Assisted Enteroscopy: A Korean Association for the Study of Intestinal Disease (KASID) Multicenter Study
  Jihye Park, Jin Su Kim, Joo Hye Song, Kwangwoo Nam, Seong-Eun Kim, Eui Sun Jeong, Jae Hyun Kim, Seong Ran Jeon
  Gut and Liver.2024; 18(4): 686.     CrossRef

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 1 of the statements comprised 2 parts: risk of TB infection Recommendaduring anti-TNF therapy, and screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Citations

Citations to this article as recorded by  

• Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study
  Rongbei Liu, Zhilun Li, Lingna Ye, Jing Hu, Jian Tang, Baili Chen, Xiuli Chen, Bei Tan, Yubei Gu, Chen Xie, Chunhui Ouyang, Xiaomei Song, Fan Li, Yanyun Fan, Haixia Ren, Liangru Zhu, Min Chen, Wenyu Jiang, Qian Cao
  Inflammatory Bowel Diseases.2024; 30(1): 45.     CrossRef
• (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review
  Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange
  Clinical Microbiology and Infection.2024; 30(8): 989.     CrossRef
• Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease
  Vineet Ahuja, Ida Hilmi, Byong Duk Ye, Khoon Lin Ling, Siew C. Ng, Rupert W. Leong, Peeyush Kumar, Xin Hui Khoo, Govind K. Makharia, Jose Sollano, Pises Pisespongsa, Nazri Mustaffa, Rupa Banerjee, Alex Hwong‐Ruey Leow, Raja Affendi Raja Ali, Sai Wei Chuah
  Journal of Gastroenterology and Hepatology.2024; 39(8): 1500.     CrossRef
• Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
  Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
  Intestinal Research.2023; 21(1): 61.     CrossRef
• Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients
  Flora Maria Lorenzo Fortes, Raquel Rocha, Genoile Oliveira Santana
  World Journal of Gastroenterology.2023; 29(9): 1536.     CrossRef
• Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
  Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
  Clinical Endoscopy.2023; 56(2): 239.     CrossRef
• Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
  Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
  ACG Case Reports Journal.2023; 10(6): e01066.     CrossRef
• Intestinal tuberculosis can masquerade as Crohn’s disease: A teachable moment
  Pooja KC, Madhur Bhattarai, Subodh Adhikari, Prakriti Parajuli, Sujata Bhandari, Himal Bikram Bhattarai, Niraj Kumar Sharma, Shailendra Karki, Suryakiran Acharya, Bibhusan Basnet
  SAGE Open Medical Case Reports.2023;[Epub]     CrossRef
• The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report
  Yuya Sugiyama, Nobuhiro Ueno, Shion Tachibana, Yu Kobayashi, Yuki Murakami, Takahiro Sasaki, Aki Sakatani, Keitaro Takahashi, Katsuyoshi Ando, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura, Mikihiro Fujiya
  Medicine.2023; 102(28): e34331.     CrossRef
• Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis
  Sayan Malakar, Srikanth Kothalkar, Umair Shamsul Hoda, Uday C Ghoshal
  Cureus.2023;[Epub]     CrossRef
• Crohn’s disease and intestinal tuberculosis: challenging from every angle
  Andreia Guimarães, João Gama, Luis Curvo-Semedo, António Canaveira Manso
  BMJ Case Reports.2023; 16(12): e254400.     CrossRef
• Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
  Jae Hoon Jung, Sujin Choi, Youra Kang, Dae-Chul Cho, So Mi Lee, Tae In Park, Byung-Ho Choe, Dongsub Kim, Ben Kang
  Frontiers in Pediatrics.2022;[Epub]     CrossRef
• Increased Risk of Infection With High Infliximab Trough Level
  Suprabhat Giri, Harish Darak
  Journal of Clinical Gastroenterology.2022; 56(4): 374.     CrossRef
• Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
  Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung
  Journal of Personalized Medicine.2022; 12(3): 507.     CrossRef
• Evidence-Based Commentary: Testing and Treating Latent Tuberculosis Before Starting Biologics and Small Molecules in Patients with Inflammatory Bowel Disease
  Rinkalben Kakadiya, Vishal Sharma
  Journal of Gastrointestinal Infections.2022; 12(02): 128.     CrossRef
• Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors
  Kyuwon Kim, Kyung-Wook Jo, Tae Sun Shim, Jin Hwa Park, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
  Sujin Choi, Bong Seok Choi, Byung-Ho Choe, Ben Kang
  Yeungnam University Journal of Medicine.2021; 38(3): 251.     CrossRef
• Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
  Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
  Intestinal Research.2021; 19(4): 419.     CrossRef
• Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region
  Lingna Ye, Thomas P. Chapman, Zhenzhen Wen, Lang Lin, Yun Qiu, Zhanju Liu, Zhihua Ran, Jiaming Qian, Kaichun Wu, Xiang Gao, Pinjin Hu, Minhu Chen, Simon P. L. Travis, Qian Cao
  Alimentary Pharmacology & Therapeutics.2021; 53(3): 390.     CrossRef
• Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
  Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul
  Gut and Liver.2020; 14(6): 685.     CrossRef
• Increased Risk of Herpes Zoster in Young and Metabolically Healthy Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
  Hosim Soh, Jaeyoung Chun, Kyungdo Han, Seona Park, Gukhwan Choi, Jihye Kim, Jooyoung Lee, Jong Pil Im, Joo Sung Kim
  Gut and Liver.2019; 13(3): 333.     CrossRef
• Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center
  Mafalda Sousa, Inês Ladeira, Ana Ponte, Carlos Fernandes, Adélia Rodrigues, Ana P. Silva, João Silva, Catarina Gomes, Edgar Afeto, João Carvalho
  European Journal of Gastroenterology & Hepatology.2019; 31(9): 1099.     CrossRef
• The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
  Joyce WY Mak, Joseph JY Sung
  Journal of Gastroenterology and Hepatology.2019; 34(8): 1269.     CrossRef
• Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
  Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
  International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
• Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
  Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
  The Korean Journal of Gastroenterology.2019; 74(3): 168.     CrossRef
• Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)
  
  Intestinal Research.2018; 16(2): 178.     CrossRef
• High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
  Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
  Intestinal Research.2018; 16(4): 588.     CrossRef
• Risk of infection associated with anti-TNF-α therapy
  Mario Fernández-Ruiz, José María Aguado
  Expert Review of Anti-infective Therapy.2018; 16(12): 939.     CrossRef

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised 3 parts: management of latent TB in preparation for anti-TNF therapy, monitoring during anti-TNF therapy, and management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Citations

Citations to this article as recorded by  

• Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study
  Rongbei Liu, Zhilun Li, Lingna Ye, Jing Hu, Jian Tang, Baili Chen, Xiuli Chen, Bei Tan, Yubei Gu, Chen Xie, Chunhui Ouyang, Xiaomei Song, Fan Li, Yanyun Fan, Haixia Ren, Liangru Zhu, Min Chen, Wenyu Jiang, Qian Cao
  Inflammatory Bowel Diseases.2024; 30(1): 45.     CrossRef
• Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects
  Yibing Hu, Zhenping Wu, Xiaoyun Yang, Jin Ding, Qunying Wang, Hao Fang, Lujian Zhu, Minli Hu
  BMC Microbiology.2024;[Epub]     CrossRef
• Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
  Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
  Journal of Gastroenterology and Hepatology.2023; 38(4): 523.     CrossRef
• Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
  Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
  Intestinal Research.2023; 21(1): 61.     CrossRef
• Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
  Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
  ACG Case Reports Journal.2023; 10(6): e01066.     CrossRef
• IBD barriers across the continents – East Asia
  Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
  Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
• Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
  Jae Hoon Jung, Sujin Choi, Youra Kang, Dae-Chul Cho, So Mi Lee, Tae In Park, Byung-Ho Choe, Dongsub Kim, Ben Kang
  Frontiers in Pediatrics.2022;[Epub]     CrossRef
• A case of paradoxical response during anti-tuberculosis treatment in a patient with ulcerative colitis
  Shuhei Hosomi, Naoko Sugita, Atsushi Kanamori, Masaki Ominami, Koji Otani, Noriko Kamata, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Yasuhiro Fujiwara
  Clinical Journal of Gastroenterology.2022; 15(3): 592.     CrossRef
• Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study
  Fen Liu, Jian Tang, Lingna Ye, Jinyu Tan, Yun Qiu, Fan Hu, Jinshen He, Baili Chen, Yao He, Zhirong Zeng, Ren Mao, Qian Cao, Xiang Gao, Minhu Chen
  Clinical and Translational Gastroenterology.2022; 13(6): e00493.     CrossRef
• Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
  Sujin Choi, Bong Seok Choi, Byung-Ho Choe, Ben Kang
  Yeungnam University Journal of Medicine.2021; 38(3): 251.     CrossRef
• Current status of inflammatory bowel diseases in Korea
  Suk-Kyun Yang
  Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
• Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
  Yunho Jung
  The Korean Journal of Gastroenterology.2020; 75(1): 1.     CrossRef
• Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
  Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
  The Korean Journal of Gastroenterology.2020; 75(1): 29.     CrossRef
• Preoperative hypoalbuminemia is an independent risk factor for postoperative complications in Crohn's disease patients with normal BMI: A cohort study
  Xiaolong Ge, Huaying Liu, Shasha Tang, Yan Wu, Yipeng Pan, Wei Liu, Weilin Qi, Lingna Ye, Qian Cao, Wei Zhou
  International Journal of Surgery.2020; 79: 294.     CrossRef
• Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
  Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul
  Gut and Liver.2020; 14(6): 685.     CrossRef
• Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
  Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
  International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
• Translating the gut microbiome: ready for the clinic?
  Susan V. Lynch, Siew C. Ng, Fergus Shanahan, Herbert Tilg
  Nature Reviews Gastroenterology & Hepatology.2019; 16(11): 656.     CrossRef
• Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
  Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
  The Korean Journal of Gastroenterology.2019; 74(3): 168.     CrossRef
• Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)
  
  Intestinal Research.2018; 16(2): 178.     CrossRef
• A rare case of disseminated histoplasmosis in a patient with Crohn’s disease on immunosuppressive treatment
  Bhavesh Bhut, Akshay Kulkarni, Varnika Rai, Vinita Agrawal, Abhai Verma, Manoj Jain, Rungmei S K Marak, Ajai Kumar Dixit, Uday C Ghoshal
  Indian Journal of Gastroenterology.2018; 37(5): 472.     CrossRef
• High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
  Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
  Intestinal Research.2018; 16(4): 588.     CrossRef

Crohn's disease (CD) is a chronic relapsing and remitting inflammatory disease of the gastrointestinal tract. CD is rare in Taiwan and other Asian countries, but its prevalence and incidence have been steadily increasing. A steering committee was established by the Taiwan Society of Inflammatory Bowel Disease to formulate statements on the diagnosis and management of CD taking into account currently available evidence and the expert opinion of the committee. Thorough clinical, endoscopic, and histological assessments are required for accurate diagnosis of CD. Computed tomography and magnetic resonance imaging are complementary to endoscopic evaluation for disease staging and detecting complications. The goals of CD management are to induce and maintain remission, reduce the risk of complications, and improve quality of life. Corticosteroids are the mainstay for inducing re-mission. Immunomodulating and biologic therapies should be used to maintain remission. Patients should be evaluated for hepatitis B virus and tuberculosis infection prior to treatment and receive regular surveillance for cancer. These consensus statements are based on current local evidence with consideration of factors, and could be serve as concise and practical guidelines for supporting clinicians in the management of patients with CD in Taiwan.

Citations

Citations to this article as recorded by  

• Factors affecting perception and acceptance of colonoscopy in patients with inflammatory bowel disease
  Chang-Hung Liao, Peng-Jen Chen, Yu-Lueng Shih, Wei-Kuo Chang, Tsai-Yuan Hsieh, Tien-Yu Huang
  Preventive Medicine Reports.2025; 49: 102951.     CrossRef
• Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
  Jia-Feng Wu, Hsu-Heng Yen, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
  Intestinal Research.2024; 22(3): 250.     CrossRef
• Current State of CT Enterography in Diagnostics and Surgical Tactics in Crohn’s Disease (Literature Review)
  A. L. Aprosimov, D. A. Lezhnev, Yu. V. Kulezneva
  Radiology - Practice.2024; (6): 67.     CrossRef
• Suboptimal Outcomes and Retreatment Rate of Patients With Crohn's Disease After Forced Discontinuation of Biologics: A Nationwide Population‐Based Study
  Nai‐Yu Chen, Chiao‐Hsiung Chuang, Yu‐Ching Chang, Yea‐Huei Kao Yang, Peng‐Hsu Chen, Ching‐Lan Cheng
  Clinical Pharmacology & Therapeutics.2023; 114(4): 914.     CrossRef
• Health Maintenance and Preventative Care in Inflammatory Bowel Disease
  Simcha Weissman, Hannah K. Systrom, Ayrton Bangolo, Daniel Elias, Marcel Awasi, Tamer Zahdeh, Chukwuemeka E. Ogbu, Mishka Hoo Kim, Meenal Kalra, Kavya Khota, Ritu B. Kasarapu, Erasmus Mutabi, Moinulhaq Makrani, Sanskrita Nemalikanti, Jim Thomas, Joseph P.
  Journal of Clinical Gastroenterology.2023; 57(4): 325.     CrossRef
• Negative pressure wound management in perineal wound status post abdominoperineal resection and extralevator abdominoperineal excision: a meta-analysis and trial sequential analysis
  Cheng-Wei Fan, Po-Huang Chen, Hong-Jie Jhou, Yi-Chiao Cheng
  International Journal of Colorectal Disease.2023;[Epub]     CrossRef
• Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
  Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
  Intestinal Research.2023; 21(3): 339.     CrossRef
• IBD barriers across the continents – East Asia
  Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
  Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
• Extra-Colonic Malignancy in Inflammatory Bowel Disease: a Paucity of Recommendations with Weak Evidence
  Simcha Weissman, Muhammad Aziz, Matthew R. Baniqued, Mohamed Ahmed, Sameh Elias, Joseph D. Feuerstein, James H. Tabibian
  Journal of Gastrointestinal Cancer.2022; 53(3): 669.     CrossRef
• Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study
  Ni Tien, Tien-Yuan Wu, Cheng-Li Lin, Chia-Jui Wu, Chung-Y Hsu, Yi-Jen Fang, Yun-Ping Lim
  Frontiers in Medicine.2022;[Epub]     CrossRef
• Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan
  Yu‐Chiao Chiu, Chia‐Chang Chen, Chung‐Wang Ko, Szu‐Chia Liao, Hong‐Zen Yeh, Chung‐Hsin Chang
  Advances in Digestive Medicine.2021; 8(1): 40.     CrossRef
• Clinical features and treatment of inflammatory bowel disease in a low-incidence area
  Hsu-Heng Yen, Tsui-Chun Hsu, Mei-Wen Chen, Pei-Yuan Su, Yang-Yuan Chen
  Medicine.2021; 100(10): e25090.     CrossRef
• Quality assessment of clinical guidelines on probiotics therapy in children with IBD using the AGREE II instrument
  Haixin Cheng, Ziyin Ma, Boran Yu, Xiaohui Liu, Chao Tian, Xuli Zhong, Libo Zhao
  Journal of Clinical Pharmacy and Therapeutics.2021; 46(4): 1155.     CrossRef
• Clinicopathological and Molecular Features of Patients with Early and Late Recurrence after Curative Surgery for Colorectal Cancer
  Yuan-Tzu Lan, Shih-Ching Chang, Pei-Ching Lin, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Chien-Hsing Lin, Wen-Yi Liang, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Jen-Kou Lin
  Cancers.2021; 13(8): 1883.     CrossRef
• Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing)
  
  Journal of Digestive Diseases.2021; 22(6): 298.     CrossRef
• Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
  Hsu-Heng Yen, Pei-Yuan Su, Siou-Ping Huang, Lisha Wu, Tsui-Chun Hsu, Ya-Huei Zeng, Yang-Yuan Chen, Wan-Long Chuang
  PLOS ONE.2021; 16(5): e0252286.     CrossRef
• Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines
  Bing‐He Xiao, Xu‐Dong Ma, Jia‐Jun Lv, Ting Yang, Xin‐Jie Liu, Li‐Ya An, Yu‐Xing Qi, Ming‐Liang Lu, Yong‐Qing Duan, Da‐Li Sun
  International Journal of Clinical Practice.2021;[Epub]     CrossRef
• Clinical significance of granulomas in Crohn's disease: A systematic review and meta‐analysis
  Seung Wook Hong, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
  Journal of Gastroenterology and Hepatology.2020; 35(3): 364.     CrossRef
• Diagnostic efficacy of double-balloon enteroscopy in patients with suspected isolated small bowel Crohn’s disease
  Zihan Huang, Xiang Liu, Fei Yang, Guoxin Wang, Nan Ge, Sheng Wang, Jintao Guo, Siyu Sun
  BMC Gastroenterology.2020;[Epub]     CrossRef
• Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study
  Jesus K. Yamamoto-Furusho, Othman Al Harbi, Alessandro Armuzzi, Webber Chan, Enrique Ponce de Leon, Jiaming Qian, Marina Shapina, Murat Toruner, Chia-Hung Tu, Byong Duk Ye, Morgane Guennec, Cecilia Sison, Dirk Demuth, Olga Fadeeva, Qasim M. Rana Khan
  Digestive and Liver Disease.2020; 52(8): 869.     CrossRef
• Strengthened monitoring and optimized management of Crohn’s disease patients
  Jing-Jing Wang, Yi-Hong Fan, Rong Huang
  World Chinese Journal of Digestology.2020; 28(15): 660.     CrossRef
• Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
  Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul
  Gut and Liver.2020; 14(6): 685.     CrossRef
• Innovative Animal Model of DSS-Induced Ulcerative Colitis in Pseudo Germ-Free Mice
  Sona Gancarcikova, Stanislav Lauko, Gabriela Hrckova, Zuzana Andrejcakova, Vanda Hajduckova, Marian Madar, Livia Kolesar Fecskeova, Dagmar Mudronova, Kristina Mravcova, Gabriela Strkolcova, Radomira Nemcova, Jana Kacirova, Andrea Staskova, Stefan Vilcek,
  Cells.2020; 9(12): 2571.     CrossRef
• Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates
  Hau-Jyun Su, Yu-Tse Chiu, Chuan-Tai Chiu, Yen-Chun Lin, Chen-Yu Wang, Jui-Ying Hsieh, Shu-Chen Wei
  Journal of the Formosan Medical Association.2019; 118(7): 1083.     CrossRef
• Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study
  Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei
  Intestinal Research.2019; 17(1): 54.     CrossRef
• Response to Chamberlin and Borody
  Gary R. Lichtenstein, Edward V. Loftus, Kim L. Isaacs, Miguel D. Regueiro, Bruce E. Sands
  American Journal of Gastroenterology.2019; 114(1): 171.     CrossRef
• Immunogenicity of biologic therapies: causes and consequences
  Wolf-Henning Boehncke, Nicolo Costantino Brembilla
  Expert Review of Clinical Immunology.2018; 14(6): 513.     CrossRef
• Changing treatment paradigms for the management of inflammatory bowel disease
  Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
  The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
• Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study
  Ya-Chih Tien, Hsu-Heng Yen, Ching-Fang Li, Mei-Ping Liu, Yin-Tzu Hsue, Ming-Hui Hung, Ying-Ming Chiu
  Arthritis Research & Therapy.2018;[Epub]     CrossRef
• Balloon-Assisted Enteroscopy and Capsule Endoscopy in Suspected Small Bowel Crohn’s Disease
  Hsu-Heng Yen, Chen-Wang Chang, Jen-Wei Chou, Shu-Chen Wei
  Clinical Endoscopy.2017; 50(5): 417.     CrossRef

Ulcerative colitis (UC) is an inflammatory bowel disease characterized by chronic mucosal inflammation of the colon, and the prevalence and incidence of UC have been steadily increasing in Taiwan. A steering committee was established by the Taiwan Society of Inflammatory Bowel Disease to formulate statements on the diagnosis and management of UC taking into account currently available evidence and the expert opinion of the committee. Accurate diagnosis of UC requires thorough clinical, endoscopic, and histological assessment and careful exclusion of differential diagnoses, particularly infectious colitis. The goals of UC therapy are to induce and maintain remission, reduce the risk of complications, and improve quality of life. As outlined in the recommended treatment algorithm, choice of treatment is dictated by severity, extent, and course of disease. Patients should be evaluated for hepatitis B virus and tuberculosis infection prior to immunosuppressive treatment, especially with steroids and biologic agents, and should be regularly monitored for reactivation of latent infection. These consensus statements are also based on current local evidence with consideration of factors, and could be serve as concise and practical guidelines for supporting clinicians in the management of UC in Taiwan.

Citations

Citations to this article as recorded by  

• Factors affecting perception and acceptance of colonoscopy in patients with inflammatory bowel disease
  Chang-Hung Liao, Peng-Jen Chen, Yu-Lueng Shih, Wei-Kuo Chang, Tsai-Yuan Hsieh, Tien-Yu Huang
  Preventive Medicine Reports.2025; 49: 102951.     CrossRef
• Clinical Characteristics, Management, and Outcomes of Colitis-Associated Colorectal Cancer and the Comparison With Sporadic Colorectal Cancer in Taiwan
  Hsin-Yun Wu, Meng-Tzu Weng, Jen-Wei Chou, Hsu-Heng Yen, Chun-Chi Lin, Feng-Fan Chiang, Chen-Shuan Chung, Wei-Chen Lin, Chen-Wang Chang, Puo-Hsien Le, Chia-Jung Kuo, Ching-Pin Lin, Wen-Hung Hsu, Chiao-Hsiung Chuang, Tzung-Jiun Tsai, I-Che Feng, Shu-Chen We
  Clinical and Translational Gastroenterology.2025; 16(2): e00798.     CrossRef
• Moxifloxacin promotes two-photon microscopic imaging for discriminating different stages of DSS-induced colitis on mice
  Yingtong Chen, Xiaoyi Xu, Min Wang, Xiang Wang, Yan Wang, Yong Zhang, Jin Huang, Yuwen Tao, Wentao Fan, Lili Zhao, Li Liu, Zhining Fan
  Photodiagnosis and Photodynamic Therapy.2024; 48: 104220.     CrossRef
• High prevalence of vitamin D deficiency in Taiwanese patients with inflammatory bowel disease
  Chen-Ta Yang, Hsu-Heng Yen, Pei-Yuan Su, Yang-Yuan Chen, Siou-Ping Huang
  Scientific Reports.2024;[Epub]     CrossRef
• Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
  Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
  Intestinal Research.2024; 22(3): 213.     CrossRef
• Systemic Immune-Inflammation Index: Unveiling the Diagnostic Potential in Ulcerative Colitis through a Comprehensive Systematic Review and Meta-Analysis
  Anas Elgenidy, Omar Alomari, Tasbih Emad, Sara K. Kamal, Islam E. Al Ghanam, Aya Sherif, Mohammed Al-mahdi Al-kurdi, Abdallah A. Helal, Yusof Mohamed Omar, Mohamed Rafiek Ramadan
  Gastroenterology & Endoscopy.2024;[Epub]     CrossRef
• Real‐world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan
  Hsu‐Heng Yen, Yu‐Chun Hsu, Chu‐Hsuan Kuo, Tsui‐Chun Hsu, Yang‐Yuan Chen
  Advances in Digestive Medicine.2023; 10(1): 28.     CrossRef
• Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice
  Kun-Yu Tsai, Jeng-Fu You, Tzong-Yun Tsai, Yih Jong Chern, Yu-Jen Hsu, Shu-Huan Huang, Wen-Sy Tsai
  Intestinal Research.2023; 21(1): 100.     CrossRef
• Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study
  Wei-Chen Lin, Wei-Chen Tai, Chung-Hsin Chang, Chia-Hung Tu, I-Che Feng, Ming-Jium Shieh, Chen-Shuan Chung, Hsu-Heng Yen, Jen-Wei Chou, Jau-Min Wong, Yu-Hwa Liu, Tien-Yu Huang, Chiao-Hsiung Chuang, Tzung-Jiun Tsai, Feng-Fan Chiang, Chien-Yu Lu, Wen-Hung Hs
  Inflammatory Bowel Diseases.2023; 29(11): 1730.     CrossRef
• Health Maintenance and Preventative Care in Inflammatory Bowel Disease
  Simcha Weissman, Hannah K. Systrom, Ayrton Bangolo, Daniel Elias, Marcel Awasi, Tamer Zahdeh, Chukwuemeka E. Ogbu, Mishka Hoo Kim, Meenal Kalra, Kavya Khota, Ritu B. Kasarapu, Erasmus Mutabi, Moinulhaq Makrani, Sanskrita Nemalikanti, Jim Thomas, Joseph P.
  Journal of Clinical Gastroenterology.2023; 57(4): 325.     CrossRef
• Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
  Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
  Intestinal Research.2023; 21(3): 339.     CrossRef
• Association between ulcerative colitis and Helicobacter pylori infection: A case-control study
  Iyad Ali, Qusay Abdo, Shayma'a M. Al-Hihi, Ansam Shawabkeh
  Heliyon.2022; 8(2): e08930.     CrossRef
• Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study
  Ni Tien, Tien-Yuan Wu, Cheng-Li Lin, Chia-Jui Wu, Chung-Y Hsu, Yi-Jen Fang, Yun-Ping Lim
  Frontiers in Medicine.2022;[Epub]     CrossRef
• Discovery and Validation of Potential Serum Biomarkers with Pro-Inflammatory and DNA Damage Activities in Ulcerative Colitis: A Comprehensive Untargeted Metabolomic Study
  Mingxiao Li, Rui Zhang, Mingjie Xin, Yi Xu, Shijia Liu, Boyang Yu, Boli Zhang, Jihua Liu
  Metabolites.2022; 12(10): 997.     CrossRef
• Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease
  Shun-Wen Hsiao, Hsu-Heng Yen, Yang-Yuan Chen
  Gut and Liver.2022; 16(6): 840.     CrossRef
• Serum homocysteine level was elevated in ulcerative colitis and can be applied as diagnostic biomarker
  Xiaoping Zhang, Shanshan Wang, Hongmin Wang, Junxia Wu, Qihua Tan
  Pteridines.2022; 33(1): 87.     CrossRef
• Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan
  Yu‐Chiao Chiu, Chia‐Chang Chen, Chung‐Wang Ko, Szu‐Chia Liao, Hong‐Zen Yeh, Chung‐Hsin Chang
  Advances in Digestive Medicine.2021; 8(1): 40.     CrossRef
• Clinical features and treatment of inflammatory bowel disease in a low-incidence area
  Hsu-Heng Yen, Tsui-Chun Hsu, Mei-Wen Chen, Pei-Yuan Su, Yang-Yuan Chen
  Medicine.2021; 100(10): e25090.     CrossRef
• Comparison of outcomes of cyclosporine A and infliximab for steroid‐refractory acute severe ulcerative colitis
  Eun Mi Song, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Byong Duk Ye
  Journal of Gastroenterology and Hepatology.2021; 36(9): 2463.     CrossRef
• Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
  Hsu-Heng Yen, Pei-Yuan Su, Siou-Ping Huang, Lisha Wu, Tsui-Chun Hsu, Ya-Huei Zeng, Yang-Yuan Chen, Wan-Long Chuang
  PLOS ONE.2021; 16(5): e0252286.     CrossRef
• Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines
  Bing‐He Xiao, Xu‐Dong Ma, Jia‐Jun Lv, Ting Yang, Xin‐Jie Liu, Li‐Ya An, Yu‐Xing Qi, Ming‐Liang Lu, Yong‐Qing Duan, Da‐Li Sun
  International Journal of Clinical Practice.2021;[Epub]     CrossRef
• Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?
  Shaghayegh Baradaran Ghavami, Hamid Asadzadeh Aghdaei, Dario Sorrentino, Shabnam Shahrokh, Maryam Farmani, Fatemeh Ashrafian, Maria Pina Dore, Shahrbanoo Keshavarz Azizi Raftar, Seyed Mobin Khoramjoo, Mohammad Reza Zali
  International Journal of Molecular Sciences.2021; 22(15): 8274.     CrossRef
• Efficacy and safety of Etiasa for treatment of mild-to-moderate ulcerative colitis: A Meta-analysis
  Fang-Mei Ling, Fei-Nan Lu, Sheng-Nan Wang, Liang-Ru Zhu
  World Chinese Journal of Digestology.2021; 29(15): 880.     CrossRef
• Association between Ulcerative Colitis and Helicobacter pylori Infection: A Case-Control Study
  Iyad Ali, Qusay Abdo, Shayma’a M. Al-Hihi, Ansam Shawabkeh
  SSRN Electronic Journal .2021;[Epub]     CrossRef
• A case with cytomegalovirus colitis and toxic megacolon initially diagnosed as Crohn's disease
  Shan-Han Chang, Hsin-Yun Sun, Chia-Tung Shun, Shu-Chen Wei
  Journal of the Formosan Medical Association.2020; 119(9): 1442.     CrossRef
• Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study
  Jesus K. Yamamoto-Furusho, Othman Al Harbi, Alessandro Armuzzi, Webber Chan, Enrique Ponce de Leon, Jiaming Qian, Marina Shapina, Murat Toruner, Chia-Hung Tu, Byong Duk Ye, Morgane Guennec, Cecilia Sison, Dirk Demuth, Olga Fadeeva, Qasim M. Rana Khan
  Digestive and Liver Disease.2020; 52(8): 869.     CrossRef
• Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis
  Hsu-Heng Yen, Mei-Wen Chen, Yu-Yao Chang, Hsuan-Yuan Huang, Tsui-Chun Hsu, Yang-Yuan Chen
  PeerJ.2020; 8: e9537.     CrossRef
• Ulcerative colitis
  Taku Kobayashi, Britta Siegmund, Catherine Le Berre, Shu Chen Wei, Marc Ferrante, Bo Shen, Charles N. Bernstein, Silvio Danese, Laurent Peyrin-Biroulet, Toshifumi Hibi
  Nature Reviews Disease Primers.2020;[Epub]     CrossRef
• Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
  Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul
  Gut and Liver.2020; 14(6): 685.     CrossRef
• To assess the effective and safety of berberine hydrochloride in ulcerative colitis
  Yong Zhang, Jin Wang, Daorui Hou, Shuguang Yan, Sijie Dang
  Medicine.2020; 99(49): e23482.     CrossRef
• Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates
  Hau-Jyun Su, Yu-Tse Chiu, Chuan-Tai Chiu, Yen-Chun Lin, Chen-Yu Wang, Jui-Ying Hsieh, Shu-Chen Wei
  Journal of the Formosan Medical Association.2019; 118(7): 1083.     CrossRef
• Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study
  Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei
  Intestinal Research.2019; 17(1): 54.     CrossRef
• Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
  Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
  Intestinal Research.2019; 17(3): 349.     CrossRef
• Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response
  Wei-Chen Lin, Chen-Wang Chang, Ming-Jen Chen, Tzu-Chi Hsu, Horng-Yuan Wang
  Medicine.2019; 98(21): e15748.     CrossRef
• Ulcerative Colitis in Elderly People: An Emerging Issue
  Wei-Chen Lin, Ming-Jen Chen, Cheng-Hsin Chu, Tsang-En Wang, Horng-Yuan Wang, Chen-Wang Chang
  International Journal of Gerontology.2018;[Epub]     CrossRef
• Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea
  Ji Young Chang, Sung-Ae Jung, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Ki-Nam Shim
  Intestinal Research.2018; 16(4): 599.     CrossRef
• Efficacy and Safety of Hou Gu Mi Xi on Spleen Qi Deficiency in Patients with Nonorganic Gastrointestinal Disorders: Protocol for a Multicenter, Randomized, Placebo‐Controlled Trial
  Xiaofan Chen, Heyun Nie, Wenjun Liu, Xu Zhou, Jianhua Nie, Bin Xie, Dongping Chen, Yiping Jiang, Kunhe Zhang, Ying Fu, Deping Yang, Yan Xiong, Zhangyang Zhao, Xin Sun, Weifeng Zhu, Carmen Mannucci
  Evidence-Based Complementary and Alternative Medicine.2018;[Epub]     CrossRef
• Challenges in the diagnosis of ulcerative colitis with concomitant bacterial infections and chronic infectious colitis
  Wei-Chen Lin, Chen-Wang Chang, Ming-Jen Chen, Cheng-Hsin Chu, Shou-Chuan Shih, Tzu-Chi Hsu, Horng-Yang Wang, John Green
  PLOS ONE.2017; 12(12): e0189377.     CrossRef

Citations

Citations to this article as recorded by  

• Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
  Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
  Therapeutic Advances in Gastroenterology.2024;[Epub]     CrossRef
• Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy
  Ahmed B. Bayoumy, A. R. Ansari, C. J. J. Mulder, K. Schmiegelow, Timothy Florin, N. K. H. De Boer
  Clinical Pharmacokinetics.2024; 63(8): 1089.     CrossRef
• Azathioprine for people with multiple sclerosis
  Ben Ridley, Francesco Nonino, Elisa Baldin, Ilaria Casetta, Gerardo Iuliano, Graziella Filippini
  Cochrane Database of Systematic Reviews.2024;[Epub]     CrossRef
• Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
  Jiryeon Jang, Sehoon Jeong
  BioChip Journal.2023; 17(4): 403.     CrossRef
• Association of genetic polymorphism of NUDT15, TPMT and ITPA gene in the toxicity and efficacy of azathioprine-based regimen in Egyptian inflammatory bowel disease patients
  Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
  Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub]     CrossRef
• A review article of inflammatory bowel disease treatment and pharmacogenomics
  Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
  Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub]     CrossRef
• Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review
  Devendra Desai, Anuraag Jena, Vishal Sharma, Toshifumi Hibi
  Expert Review of Clinical Pharmacology.2023; 16(7): 643.     CrossRef
• Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
  Yoon-Zi Kim, Ben Kang, Eun-Sil Kim, Yiyoung Kwon, Yon-Ho Choe, Mi-Jin Kim
  Biomedicines.2023; 11(9): 2575.     CrossRef
• Effect of NUDT15 polymorphisms on early hematological safety of low‐dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study
  Xingli Zhou, Liangliang Cheng, Yiyi Wang, Hui Gou, Ke Ju, TianJiao Lan, Tongying Zhan, GaoJie Li, Yuanxia Gu, Yeting Sun, Yan Xu, Yukun Sun, Yanhong Zhou, Wei Li
  The Journal of Dermatology.2022; 49(4): 402.     CrossRef
• Use of thiopurines in inflammatory bowel disease: an update
  Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, Amit Kumar Dutta, Abhinav Anand, Charles N. Bernstein, Devendra Desai, C. Ganesh Pai, Govind Makharia, Harsh Vardhan Tevethia, Joyce WY Mak, Kirandeep Kaur, Kiran Peddi, Mukesh Kumar Ranjan, Perttu Arkkila, Ra
  Intestinal Research.2022; 20(1): 11.     CrossRef
• Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder
  Wenjuan Huang, Liang Wang, Junhui Xia, Wenyu Li, Min Wang, Jian Yu, Qinying Li, Bei Wang, Juyuan Pan, Lei Du, Jianhua Ma, Hongmei Tan, Xuechun Chang, Chuanzhen Lu, Chongbo Zhao, Jiahong Lu, Lei Zhou, Jingzi ZhangBao, Chao Quan
  European Journal of Neurology.2022; 29(8): 2343.     CrossRef
• Minimal risk of lymphoma and non‐melanoma skin cancer despite long‐term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India
  Mukesh Kumar Ranjan, Bhaskar Kante, Sudheer Kumar Vuyyuru, Peeyush Kumar, Sandeep K Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
  Journal of Gastroenterology and Hepatology.2022; 37(8): 1544.     CrossRef
• NUDT15Genotyping in Thiopurine Drug Therapy
  Jong Kwon Lee, Rihwa Choi, Soo-Youn Lee
  Laboratory Medicine Online.2022; 12(4): 217.     CrossRef
• Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis
  Qiang Miao, Lin Yan, Yanhong Zhou, Yi Li, Yuangao Zou, Lanlan Wang, Yangjuan Bai, Junlong Zhang
  Scientific Reports.2021;[Epub]     CrossRef
• Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
  You Sun Kim
  Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
• Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease
  Kang Chao, Yibiao Huang, Xia Zhu, Jian Tang, Xueding Wang, Lang Lin, Huili Guo, Caibin Zhang, Miao Li, Qingfan Yang, Jie Huang, Lingna Ye, Pinjin Hu, Min Huang, Qian Cao, Xiang Gao
  Alimentary Pharmacology & Therapeutics.2021; 54(9): 1124.     CrossRef
• NUDT15: A bench to bedside success story
  Ann M. Moyer
  Clinical Biochemistry.2021; 92: 1.     CrossRef
• Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations
  Kanyarat Khaeso, Sariya Udayachalerm, Patcharee Komvilaisak, Su-on Chainansamit, Kunanya Suwannaying, Napat Laoaroon, Pitchayanan Kuwatjanakul, Nontaya Nakkam, Chonlaphat Sukasem, Apichaya Puangpetch, Wichittra Tassaneeyakul, Nathorn Chaiyakunapruk
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
  Ji Young Chang, Jae Hee Cheon
  Precision and Future Medicine.2021; 5(4): 151.     CrossRef
• Sexual Dysfunction and Fertility Problems in Men with Inflammatory Bowel Disease
  Yong Eun Park, Tae Oh Kim
  The World Journal of Men's Health.2020; 38(3): 285.     CrossRef
• Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases
  Ji Young Chang, Soo Jung Park, Eun Suk Jung, Sung-Ae Jung, Chang Mo Moon, Jaeyoung Chun, Jae Jun Park, Eun Sun Kim, Yehyun Park, Tae-Il Kim, Won Ho Kim, Jae Hee Cheon
  Clinical Gastroenterology and Hepatology.2020; 18(9): 2010.     CrossRef
• Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
  Hiroshi Nakase
  Gut and Liver.2020; 14(1): 7.     CrossRef
• Adjustment of azathioprine dose should be based on a lower 6‐TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers
  Ben Kang, Tae Jun Kim, Jaeyoung Choi, Sun‐Young Baek, Soohyun Ahn, Rihwa Choi, Soo‐Youn Lee, Yon Ho Choe
  Alimentary Pharmacology & Therapeutics.2020; 52(3): 459.     CrossRef
• NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy
  Ye Xu, Yu-Qi Qiao, Han-Yang Li, Mi Zhou, Chen-Wen Cai, Jun Shen, Zhi-Hua Ran
  Gastroenterology Report.2020; 8(6): 437.     CrossRef
• Complete remission of refractory pemphigus vulgaris in a Chinese patient with mutated NUDT15 by combination of minimal doses of azathioprine and prednisone
  Xing‐Li Zhou, Tong‐Ying Zhan, Yan‐Hong Zhou, Krista Shrestha, Tian‐Jiao Lan, Wei Li
  Dermatologic Therapy.2020;[Epub]     CrossRef
• Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn’s disease who turned out to possess homozygous mutations in NUDT15 R139C
  Jaewoan Bae, Byung-Ho Choe, Ben Kang
  Yeungnam University Journal of Medicine.2020; 37(4): 332.     CrossRef
• NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine‐induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India
  Rupa Banerjee, Vishnubhotla Venkata Ravikanth, Partha Pal, Govardhan Bale, Urmila Steffie Avanthi, Idan Goren, B. Ganesh Girish, Sasikala Mitnala, D. Nageshwar Reddy
  Alimentary Pharmacology & Therapeutics.2020; 52(11-12): 1683.     CrossRef
• Improving the quality of care for inflammatory bowel disease
  Byong Duk Ye, Simon Travis
  Intestinal Research.2019; 17(1): 45.     CrossRef
• NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis
  Xiaoli Fan, Dandan Yin, Ruoting Men, Heng Xu, Li Yang
  Frontiers in Pharmacology.2019;[Epub]     CrossRef
• Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics
  Ji Young Chang, Jae Hee Cheon
  Digestive Diseases and Sciences.2019; 64(9): 2395.     CrossRef
• Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients
  Xia Zhu, Kang Chao, Miao Li, Wen Xie, Hong Zheng, Jin-Xin Zhang, Pin-Jin Hu, Min Huang, Xiang Gao, Xue-Ding Wang
  World Journal of Gastroenterology.2019; 25(38): 5850.     CrossRef
• How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
  You Sun Kim
  The Korean Journal of Gastroenterology.2018; 71(2): 74.     CrossRef
• Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis
  Sarah Cargnin, Armando A. Genazzani, Pier Luigi Canonico, Salvatore Terrazzino
  Pharmacological Research.2018; 135: 102.     CrossRef
• Treatment of Autoimmune Bullous Disorders in Pregnancy
  Carolyn J. Kushner, Josef Symon S. Concha, Victoria P. Werth
  American Journal of Clinical Dermatology.2018; 19(3): 391.     CrossRef
• Characteristics and management of patients with inflammatory bowel disease between a secondary and tertiary hospitals: a propensity score analysis
  Ki Hwan Song, Eun Soo Kim, Yoo Jin Lee, Byung Ik Jang, Kyeong Ok Kim, Sang Gyu Kwak, Hyun Seok Lee
  Intestinal Research.2018; 16(2): 216.     CrossRef
• Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
  Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Intestinal Research.2018; 16(1): 4.     CrossRef
• Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
  Hong-Hui Wang, Ying He, Hong-Xian Wang, Cheng-Ling Liao, Yu Peng, Li-Jian Tao, Wei Zhang, Hui-Xiang Yang
  World Journal of Gastroenterology.2018; 24(8): 941.     CrossRef
• NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients
  Xiang Fei, Qing Shu, Huaijun Zhu, Bingzhu Hua, Shiying Wang, Ling Guo, Yun Fang, Weihong Ge
  Frontiers in Pharmacology.2018;[Epub]     CrossRef
• Pharmacotherapy of ulcerative colitis – current status and emerging trends
  Hilal Ahmad, Vijay L. Kumar
  Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(6): 581.     CrossRef
• Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
  Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
  Journal of Gastroenterology and Hepatology.2018; 33(1): 20.     CrossRef
• Postoperative course of Crohn disease according to timing of bowel resection
  Ji Min Lee, Kang-Moon Lee, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, Dong Soo Han, Chang Kyun Lee, Hyun-Ju Park
  Medicine.2018; 97(16): e0459.     CrossRef
• Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
  Sheng Zhang Lim, Eng Wee Chua
  Frontiers in Pharmacology.2018;[Epub]     CrossRef
• Changing treatment paradigms for the management of inflammatory bowel disease
  Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
  The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
• NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
  Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura
  Intestinal Research.2017; 15(3): 328.     CrossRef
• Second Korean Guideline for the Management of Ulcerative Colitis
  Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
  The Korean Journal of Gastroenterology.2017; 69(1): 1.     CrossRef
• Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
  Jong Pil Im
  Intestinal Research.2017; 15(2): 147.     CrossRef
• Second Korean guidelines for the management of ulcerative colitis
  Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
  Intestinal Research.2017; 15(1): 7.     CrossRef
• Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease
  Kang Chao, Xueding Wang, Qian Cao, Jiaming Qian, Kaichun Wu, Xia Zhu, Hong Yang, Jie Liang, Lang Lin, Zicheng Huang, Yu Zhang, Yibiao Huang, Yinghao Sun, Xianmin Xue, Min Huang, Pinjin Hu, Ping Lan, Xiang Gao
  Inflammatory Bowel Diseases.2017; 23(9): 1592.     CrossRef
• Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
  Abhinav Vasudevan, Peter R Gibson, Daniel R van Langenberg
  World Journal of Gastroenterology.2017; 23(35): 6385.     CrossRef
• Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
  Chang Soo Eun
  Gut and Liver.2017; 11(1): 3.     CrossRef
• Second Korean Guidelines for the Management of Crohn's Disease
  Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
  The Korean Journal of Gastroenterology.2017; 69(1): 29.     CrossRef
• Second Korean guidelines for the management of Crohn's disease
  Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
  Intestinal Research.2017; 15(1): 38.     CrossRef
• Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study
  Sang Hyoung Park, Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
  Digestive Diseases and Sciences.2016; 61(7): 2060.     CrossRef
• Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn’s disease patients
  Qiuyuan Liu, Yanyan Wang, Qiao Mei, Wei Han, Jing Hu, Naizhong Hu
  Scandinavian Journal of Gastroenterology.2016; 51(9): 1093.     CrossRef
• NUDT15 polymorphisms are better than thiopurine S‐methyltransferase as predictor of risk for thiopurine‐induced leukopenia in Chinese patients with Crohn's disease
  X. Zhu, X.‐D. Wang, K. Chao, M. Zhi, H. Zheng, H.‐L. Ruan, S. Xin, N. Ding, P.‐J. Hu, M. Huang, X. Gao
  Alimentary Pharmacology & Therapeutics.2016; 44(9): 967.     CrossRef
• Influences ofXDHgenotype by gene–gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn’s disease
  Soo-Kyung Park, Myunghee Hong, Byong Duk Ye, Kyung-Jo Kim, Sang Hyoung Park, Dong-Hoon Yang, Sung-Wook Hwang, Min Seob Kwak, Ho-Su Lee, Kyuyoung Song, Suk-Kyun Yang
  Scandinavian Journal of Gastroenterology.2016; 51(6): 684.     CrossRef
• Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea
  Ho-Su Lee, Jaewon Choe, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
  Intestinal Research.2016; 14(3): 258.     CrossRef
• Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease
  Ho-Su Lee, Kyung-Wook Jo, Tae Sun Shim, Jin Woo Song, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Jin-Ho Kim, Suk-Kyun Yang
  Journal of Crohn's and Colitis.2015; 9(11): 1053.     CrossRef